Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23630012 | 1.00 | NPC1 (0.31) | NPC1ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL29482315 | 0.99 | NPC1 (0.31) | NPC1ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL2967977 | 0.68 | NPC1 (0.32) | NPC1ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL13238426 | 0.65 | MAPT (0.39) | NPC1ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL388609 | 0.64 | ALDH1A1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL388608 | 0.64 | ALDH1A1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL13238425 | 0.63 | MAPT (0.39) | NPC1ALDH1A1MAPTHPGDRAB9A | |
| Pyridine SCHEMBL4442754 | 0.62 | NPC1 (0.31) | NPC1ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL28059372 | 0.60 | TACR1 (0.33) | NPC1ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL17921978 | 0.59 | MAPT (0.39) | NPC1ALDH1A1MAPTHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233768-B1 | 1,3-BUTADIENE SYNTHESIS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-02-20 | — | — | EP | claimed |
| EP-3233768-A1 | 1,3-BUTADIENE SYNTHESIS | Lanxess Deutschland GmbH (DE) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096846-A1 | 1,3-BUTADIENE SYNTHESIS | LANXESS DEUTSCHLAND GMBH (DE) | 2016-06-23 | — | — | WO | claimed |
| EP-3034486-A1 | 1,3-butadiene synthesis | LANXESS Deutschland GmbH (DE) | 2016-06-22 | — | — | EP | claimed |
| US-20120289617-A1 | Hybrid Catalyst for Olefin Metathesis | SAUDI ARABIAN OIL COMPANY (SA) | 2012-11-15 | — | — | US | claimed |
| US-20060205804-A1 | Process for preparing 5-(4-fluorophenyl)-1-[2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl) ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide | NELSON JAMES D | 2006-09-14 | — | — | US | claimed |
| EP-1615883-A1 | PROCESS FOR PREPARING 5-(4-FLUOROPHENYL)-1-[2-((2R,4R)-4-HYDROXY-6-OXO-TETRAHYDRO-PYRAN-2-YL)-ETHYL]-2-ISOPROPYL-4-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID PHENYLAMIDE | WARNER-LAMBERT COMPANY (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089894-A1 | PROCESS FOR PREPARING 5-(4-FLUOROPHENYL)-1-[2-((2R,4R)-4-HYDROXY-6-OXO-TETRAHYDRO-PYRAN-2-YL)ETHYL]-2-ISOPROPYL-4-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID PHENYLAMIDE | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | claimed |
| EP-2057205-B1 | PRODUCTION OF META-BLOCK COPOLYMERS BY POLYMER SEGMENT INTERCHANGE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-2061827-B1 | PRODUCTION OF BLOCKCOPOLYMERS BY AMORPHOUS POLYMER SEGMENT INTERCHANGE VIA METATHESIS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2592932-B1 | NOVEL TETRAHYDROPYRAZOLO[3,4-B]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2015-12-31 | — | — | US | disclosed |
| EP-2785763-A1 | FUNCTIONALIZATION OF VINYL TERMINATED POLYMERS BY RING OPENING CROSS METATHESIS | ExxonMobil Chemical Patents Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140031302-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2014-01-30 | — | — | US | disclosed |
| EP-2061826-A2 | PRODUCTION OF RANDOM BLOCKCOPOLYMERS VIA HIGH MELTING POLYMER SEGMENT METATHESIS | Dow Global Technologies Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2057205-A2 | PRODUCTION OF META-BLOCK COPOLYMERS BY POLYMER SEGMENT INTERCHANGE | Dow Global Technologies Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008125421-A1 | TRANS-ANNULAR REARRANGEMENT OF ACTIVE LACTAMES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008027267-A2 | PRODUCTION OF RANDOM BLOCKCOPOLYMERS VIA HIGH MELTING POLYMER SEGMENT METATHESIS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008027268-A2 | PRODUCTION OF BLOCKCOPOLYMERS BY AMORPHOUS POLYMER SEGMENT INTERCHANGE VIA METATHESIS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008027283-A2 | PRODUCTION OF META-BLOCK COPOLYMERS BY POLYMER SEGMENT INTERCHANGE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | NPC1 2751/4885ALDH1A1 2726/4885MAPT 978/4885 |
| US-20060205804-A1 | Process for preparing 5-(4-fluorophenyl)-1-[2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl) ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide | HMGCR, ORAI1, PKD2 | NPC1 311/4885ALDH1A1 2980/4885MAPT 1469/4885 |
| US-20140031302-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | NPC1 2920/4885ALDH1A1 2324/4885MAPT 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.